Currently Viewing:
Supplements Improving Clinical and Managed Care Outcomes in Rheumatoid arthritis: a Focus on Comparative Effecti

Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis

Allan Gibofsky, MD, JD, FACP, FCLM
Established indices focus primarily on articular measures, but do not account specifically for extra-articular manifestations. The 2012 update of the 2008 ACR RA treatment recommendations provides guidance to determine disease activity (LDA, MDA, HDA, or remission) and features of poor prognosis.32,33 Poor prognosis is associated with any of the following features of disease: functional limitation on standardized health questionnaires, extra-articular disease, positive RF, positive ACPA, or bony erosions documented by radiograph.

Conclusion

RA, a systemic autoimmune disease involving the joints and other organs, is associated with pain, disability, and mortality. Recent focus on identification of the disease earlier in the process, before extensive joint and bone damage occurs, brings hope for further improvements in the management of RA. Antigen presentation, T-cell activation, autoantibody production, TNF-α, and IL-6 are central mediators in the pathophysiology of articular and extra-articular RA. Standard disease activity indices may be used to guide treatto- target approaches to pharmacologic intervention, which is the focus of the next article in this supplement.

Author affiliation: Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY.
Funding source: This activity is supported by an educational grant from Bristol-Myers Squibb.
Author disclosure: Dr Gibofsky reports consultancy/advisory board membership, honoraria, lectureship, and stock ownership with Abbott, Amgen, Genentech, Pfizer, and UCB. He also reports stock ownership with Johnson & Johnson and GlaxoSmithKline.
Authorship information: Analysis and interpretation of data; drafting of the manuscript; and critical revision of the manuscript for important intellectual content.
Address correspondence to: Mail to: Allan Gibofsky, MD, Hospital for Special Surgery, 535 E 70th St, New York, NY 10075. E-mail: gibofskya@ hss.edu.
  1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
  2. Turesson C, Jacobsson L, Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford). 1999;38(7):668-674.
  3. Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Res Ther. 2005;7(suppl 3):S2-S8.
  4. McCain JA Jr. Unmet needs in the treatment of rheumatoid arthritis. Managed Care. 2009;18(suppl 5):1-6.
  5. Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):83-92.
  6. Gonzalez A, Kremers HM, Crowson CS, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol. 2008;35(6):1009-1014.
  7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
  8. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
  9. Helmick CG, Felson DT, Lawrence RC, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
  10. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(suppl 3):S265-S272.
  11. Gibofsky A, Winchester RJ, Patarroyo M, Fotino M, Kunkel HG. Disease associations of the Ia-like human alloantigens: contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus. J Exp Med. 1978;148(6):1728-1732.
  12. de Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol. 2009;5(4): 218-224.
  13. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7(7):391-398.
  14. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011;70(5):772-777.
  15. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol. 2010;10(8):605-611.
  16. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003;3(12):973-983.
  17. Birbara CA. Management of inadequate response to TNF-α antagonist therapy in rheumatoid arthritis: what are the options? The Internet Journal of Rheumatology. 2008;5(2). doi:10.5580/ 1ddb.
  18. Rasheed Z, Haqqi TM. Update on targets of biologic therapies for rheumatoid arthritis. Curr Rheumatol Rev. 2008;4(4):246.
  19. Combe B. Progression in early rheumatoid arthritis. Best Prac Res Clin Rheumatol. 2009;23(1):59-69.
  20. Gvozdenovic E, Koevoets R, van der Heijde D, Huizinga T, Allaart R, Landewé R. Assessment of global disease activity in RA patients monitored in the METEOR database: the patient’s versus the rheumatologist’s opinion. Ann Rheum Dis. 2012;71(suppl 3): 653.
  21. Somers TJ, Shelby RA, Keefe FJ, et al. Disease severity and domain specific arthritis self-efficacy: relationships to pain and functioning in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(6):848-856.
  22. Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol. 2011;38(6):983-989.
  23. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78(2):179-183.
  24. Machold KP. Prevention and cure of rheumatoid arthritis: is it possible? Best Prac Res Clin Rheumatol. 2010;24(3):353-361.
  25. Zufferey P, Möller B, Brulhart L, Tamborrini G, Scherer A, Ziswiler HR. Persistence of ultrasound synovitis in the patients fulfilling the DAS and/or the new ACR/EULAR RA remission definitions: results of the SONAR score applied to the patients of the SCQM cohort. Ann Rheum Dis. 2012;71(suppl 3):149.
  26. van den Broek M, Dirven L, de Vries-Bouwstra J, et al. The clinical relevance of rapid radiological progression in the first year of treatment during 8 years of follow-up of early rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(suppl 3):329.
  27. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;4292:244-257.
  28. Felson DT, Anderson JJ, Boers M, et al; American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;3896:727-735. 29. Hirano Y, Oishi Y, Yamauchi K. A comparative study of clinical composite measures (DSA28, SDAI, CDAI, Boolean) using patients with rheumatoid arthritis treated with anti-TNF agents. Ann Rheum Dis. 2012;71(suppl 3):372.
  29. Somers K, Geusens P, Elewaut D, et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun. 2011;36(1):33-46.
  30. Felson DT, Smolen JS, Wells G, et al; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-586.
  31. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
  32. Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-784.
PDF
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up